NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $6.00 +0.08 (+1.35%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.99 -0.01 (-0.15%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$5.92▼$6.1450-Day Range$5.02▼$6.6452-Week Range$4.93▼$21.79Volume125,150 shsAverage Volume373,514 shsMarket Capitalization$228.22 millionP/E RatioN/ADividend YieldN/APrice Target$25.67Consensus RatingModerate Buy Company Overview Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs. The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity. Lead programs target lysosomal storage disorders and neuromuscular diseases, with preclinical candidates optimized for tissue tropism and intracellular uptake. Entrada’s technology is designed to be modular, allowing for potential application across multiple therapeutic areas. Founded in Cambridge, Massachusetts, Entrada leverages a team with expertise in protein engineering, cell biology and drug delivery. The company serves patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations. Through continued platform development and strategic partnerships, Entrada seeks to bring novel intracellular therapies from lab to clinic.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreTRDA MarketRank™: Entrada Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 381st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingEntrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $25.67, representing about 327.8% upside from its current price of $6.00.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.12 to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.73% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 1.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.73% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Entrada Therapeutics has recently decreased by 1.85%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News SentimentN/A News SentimentEntrada Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Entrada Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $405,000.00 in company stock.Percentage Held by InsidersOnly 8.11% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesEntrada Therapeutics, Inc. - Special CallSeptember 25, 2025 | seekingalpha.comEntrada Therapeutics initiated with Early-Stage Biotech at Goldman SachsSeptember 17, 2025 | msn.comRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fund firm manager who predicted 2008 and 2020 just issued. He says if you're over 50, there's one urgent move you need to make to survive... or risk getting left behind. | Stansberry Research (Ad)Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant ProgramSeptember 5, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comEntrada (TRDA) Q2 Revenue Drops 98%August 11, 2025 | theglobeandmail.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 9, 2025 | finance.yahoo.comEntrada Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $17.29 at the beginning of 2025. Since then, TRDA shares have decreased by 65.3% and is now trading at $6.00. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) issued its quarterly earnings data on Wednesday, August, 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.18. The company earned $1.98 million during the quarter, compared to analysts' expectations of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative trailing twelve-month return on equity of 17.81%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entrada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ). Company Calendar Last Earnings8/06/2025Today10/05/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees110Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$25.67 High Price Target$29.00 Low Price Target$20.00 Potential Upside/Downside+327.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E Ratio5.36 P/E GrowthN/ANet Income$65.63 million Net Margins-92.30% Pretax Margin-96.76% Return on Equity-17.81% Return on Assets-14.55% Debt Debt-to-Equity RatioN/A Current Ratio18.64 Quick Ratio18.64 Sales & Book Value Annual Sales$210.78 million Price / Sales1.08 Cash Flow$1.59 per share Price / Cash Flow3.78 Book Value$11.46 per share Price / Book0.52Miscellaneous Outstanding Shares38,040,000Free Float34,952,000Market Cap$228.24 million OptionableOptionable Beta-0.11 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TRDA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.